Moderna (NASDAQ:MRNA – Get Rating) had its price target cut by Morgan Stanley from $209.00 to $205.00 in a research note released on Tuesday, Benzinga reports. They currently have an equal weight rating on the stock.
A number of other equities research analysts have also issued reports on the stock. Chardan Capital upped their target price on shares of Moderna from $191.00 to $208.00 and gave the stock a neutral rating in a report on Wednesday, January 18th. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $165.00 to $122.00 and set a neutral rating on the stock in a research report on Monday, October 24th. Jefferies Financial Group raised shares of Moderna from a hold rating to a buy rating and boosted their price target for the company from $170.00 to $275.00 in a research report on Monday, December 19th. Bank of America boosted their price target on shares of Moderna from $160.00 to $182.00 in a research report on Tuesday, November 15th. Finally, The Goldman Sachs Group boosted their price target on shares of Moderna from $290.00 to $296.00 and gave the company a buy rating in a research report on Thursday, October 13th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Moderna presently has an average rating of Moderate Buy and a consensus target price of $191.62.
Moderna Price Performance
Moderna stock opened at $196.76 on Tuesday. Moderna has a 52-week low of $115.03 and a 52-week high of $217.25. The firm has a market capitalization of $75.59 billion, a price-to-earnings ratio of 7.12 and a beta of 1.71. The company has a fifty day simple moving average of $185.97 and a 200-day simple moving average of $161.27. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05.
Insider Buying and Selling at Moderna
In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the company’s stock in a transaction dated Thursday, December 22nd. The shares were sold at an average price of $205.31, for a total value of $8,212,400.00. Following the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $1,111,126,633.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Moderna news, insider Juan Andres sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $201.70, for a total transaction of $403,400.00. Following the sale, the insider now directly owns 12,803 shares in the company, valued at $2,582,365.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction dated Thursday, December 22nd. The stock was sold at an average price of $205.31, for a total transaction of $8,212,400.00. Following the sale, the chief executive officer now owns 5,411,946 shares in the company, valued at $1,111,126,633.26. The disclosure for this sale can be found here. Insiders have sold 445,899 shares of company stock valued at $80,212,386 over the last 90 days. 17.30% of the stock is owned by insiders.
Institutional Trading of Moderna
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its stake in Moderna by 89.9% during the third quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock worth $761,934,000 after purchasing an additional 3,051,035 shares during the period. Theleme Partners LLP increased its stake in Moderna by 0.3% during the second quarter. Theleme Partners LLP now owns 6,354,406 shares of the company’s stock worth $907,727,000 after purchasing an additional 17,466 shares during the period. Renaissance Technologies LLC increased its stake in shares of Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after buying an additional 1,984,458 shares during the period. Northern Trust Corp increased its stake in shares of Moderna by 0.6% during the first quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock worth $603,483,000 after buying an additional 20,416 shares during the period. Finally, Banque Pictet & Cie SA increased its stake in shares of Moderna by 0.9% during the second quarter. Banque Pictet & Cie SA now owns 3,026,346 shares of the company’s stock worth $432,314,000 after buying an additional 26,863 shares during the period. 63.11% of the stock is currently owned by hedge funds and other institutional investors.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.